Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Clinical pharmacokinetics of fingolimod.

David OJ, Kovarik JM, Schmouder RL.

Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Review.

PMID:
22149256
2.

Oral treatment for multiple sclerosis.

Killestein J, Rudick RA, Polman CH.

Lancet Neurol. 2011 Nov;10(11):1026-34. doi: 10.1016/S1474-4422(11)70228-9. Review.

PMID:
22014437
3.

ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometrium.

Tanfin Z, Serrano-Sanchez M, Leiber D.

Cell Signal. 2011 Dec;23(12):1997-2004. doi: 10.1016/j.cellsig.2011.07.010. Epub 2011 Jul 22.

PMID:
21803151
4.

The outs and the ins of sphingosine-1-phosphate in immunity.

Spiegel S, Milstien S.

Nat Rev Immunol. 2011 Jun;11(6):403-15. doi: 10.1038/nri2974. Epub 2011 May 6. Review.

5.

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

Cohen JA, Chun J.

Ann Neurol. 2011 May;69(5):759-77. doi: 10.1002/ana.22426. Review.

PMID:
21520239
6.

Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS.

Wang X, Hawkins BT, Miller DS.

J Cereb Blood Flow Metab. 2011 Jun;31(6):1371-5. doi: 10.1038/jcbfm.2011.44. Epub 2011 Apr 13.

7.

Absence of PAF receptor alters cellular infiltrate but not rolling and adhesion of leukocytes in experimental autoimmune encephalomyelitis.

Rodrigues DH, Lacerda-Queiroz N, de Miranda AS, Fagundes CT, Campos RD, Arantes RE, Vilela Mde C, Rachid MA, Teixeira MM, Teixeira AL.

Brain Res. 2011 Apr 18;1385:298-306. doi: 10.1016/j.brainres.2011.02.036. Epub 2011 Feb 19.

8.

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.

Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.

9.

Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.

Wang X, Hawkins BT, Miller DS.

FASEB J. 2011 Feb;25(2):644-52. doi: 10.1096/fj.10-169227. Epub 2010 Nov 3.

10.

Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain.

ElAli A, Hermann DM.

Sci Signal. 2010 Oct 5;3(142):ra72. doi: 10.1126/scisignal.2001213.

11.

Extracellular and intracellular actions of sphingosine-1-phosphate.

Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S.

Adv Exp Med Biol. 2010;688:141-55. Review.

12.

Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay.

Hawkins BT, Rigor RR, Miller DS.

J Cereb Blood Flow Metab. 2010 Sep;30(9):1593-7. doi: 10.1038/jcbfm.2010.117. Epub 2010 Jul 14.

13.

Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.

Wang X, Sykes DB, Miller DS.

Mol Pharmacol. 2010 Sep;78(3):376-83. doi: 10.1124/mol.110.063685. Epub 2010 Jun 14.

14.

Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

Miller DS.

Trends Pharmacol Sci. 2010 Jun;31(6):246-54. doi: 10.1016/j.tips.2010.03.003. Epub 2010 Apr 24. Review.

15.

17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity.

Hartz AM, Mahringer A, Miller DS, Bauer B.

J Cereb Blood Flow Metab. 2010 Oct;30(10):1742-55. doi: 10.1038/jcbfm.2010.36. Epub 2010 Mar 10.

16.

Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.

Rigor RR, Hawkins BT, Miller DS.

J Cereb Blood Flow Metab. 2010 Jul;30(7):1373-83. doi: 10.1038/jcbfm.2010.21. Epub 2010 Mar 3.

17.

Targeting the sphingolipid signaling pathway in stroke.

Pfeilschifter W, Czech B, Neumann-Haefelin T.

Stroke. 2010 Apr;41(4):e193; author reply e194. doi: 10.1161/STROKEAHA.110.578278. Epub 2010 Feb 25. No abstract available.

18.

Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.

Hawkins BT, Sykes DB, Miller DS.

J Neurosci. 2010 Jan 27;30(4):1417-25. doi: 10.1523/JNEUROSCI.5103-09.2010.

19.

P-glycoprotein acts as an immunomodulator during neuroinflammation.

Kooij G, Backer R, Koning JJ, Reijerkerk A, van Horssen J, van der Pol SM, Drexhage J, Schinkel A, Dijkstra CD, den Haan JM, Geijtenbeek TB, de Vries HE.

PLoS One. 2009 Dec 8;4(12):e8212. doi: 10.1371/journal.pone.0008212.

20.

T lymphocytes impair P-glycoprotein function during neuroinflammation.

Kooij G, van Horssen J, de Lange EC, Reijerkerk A, van der Pol SM, van Het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE.

J Autoimmun. 2010 Jun;34(4):416-25. doi: 10.1016/j.jaut.2009.10.006. Epub 2009 Dec 2.

PMID:
19959334
Items per page

Supplemental Content

Write to the Help Desk